Review article: The potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue , 2016, Pages 27-36

  Sartor, R B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; RIFAXIMIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; RIFAMYCIN; STEROID RECEPTOR; TNF PROTEIN, HUMAN;

ANTIMICROBIAL ACTIVITY; BACTERIUM ADHERENCE; CELL FUNCTION; CROHN DISEASE; CYTOCHROME P450 3A4 GENE; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL COLITIS; HUMAN; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; MESENTERY LYMPH NODE; MICROBIAL ACTIVITY; MULTIDRUG RESISTANCE 1 GENE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; INTESTINE FLORA; INTESTINE MUCOSA; PATHOLOGY;

ANTI-BACTERIAL AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; NF-KAPPA B; RECEPTORS, STEROID; RIFAMYCINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84952881767     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13436     Document Type: Review

References (66)

1. Long MD, Hutfless S, Kappelman MD, et al,. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis 2014; 20: 398-415.
2. Kappelman MD, Moore KR, Allen JK, Cook SF,. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013; 58: 519-25.
3. Nguyen GC, Chong CA, Chong RY,. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis 2014; 8: 288-95.
4. Frank DN, Robertson CE, Hamm CM, et al,. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-84.
5. Sartor RB,. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010; 139: 1816-9.
6. Lee KA, Lee WJ,. Drosophila as a model for intestinal dysbiosis and chronic inflammatory diseases. Dev Comp Immunol 2014; 42: 102-10.
7. Sartor RB,. The intestinal microbiota in inflammatory bowel diseases. Nestle Nutr Inst Workshop Ser 2014; 79: 29-39.
8. Gevers D, Kugathasan S, Denson LA, et al,. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15: 382-92.
9. Haberman Y, Tickle TL, Dexheimer PJ, et al,. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest 2014; 124: 3617-33.
10. Knights D, Silverberg MS, Weersma RK, et al,. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med 2014; 6: 107.
11. Sartor RB,. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407.
12. Jostins L, Ripke S, Weersma RK, et al,. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24.
13. Graham DB, Xavier RJ,. From genetics of inflammatory bowel disease towards mechanistic insights. Trends Immunol 2013; 34: 371-8.
14. Knights D, Lassen KG, Xavier RJ,. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013; 62: 1505-10.
15. Kostic AD, Xavier RJ, Gevers D,. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014; 146: 1489-99.
16. Packey CD, Sartor RB,. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 2009; 22: 292-301.
17. Hansen J, Gulati A, Sartor RB,. The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Curr Opin Gastroenterol 2010; 26: 564-71.
18. Goldsmith JR, Sartor RB,. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol 2014; 49: 785-98.
19. Dogan B, Scherl E, Bosworth B, et al,. Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease. Inflamm Bowel Dis 2013; 19: 141-50.
20. Bernstein CN,. Antibiotics, probiotics and prebiotics in IBD. Nestle Nutr Inst Workshop Ser 2014; 79: 83-100.
21. Hansen JJ, Sartor RB,. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol 2015; 13: 105-20.
22. Shen B,. Acute and chronic pouchitis-pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2012; 9: 323-33.
23. Kale-Pradhan PB, Zhao JJ, Palmer JR, Wilhelm SM,. The role of antimicrobials in Crohn's disease. Expert Rev Gastroenterol Hepatol 2013; 7: 281-8.
24. Scribano ML, Prantera C,. Use of antibiotics in the treatment of Crohn's disease. World J Gastroenterol 2013; 19: 648-53.
25. Lichtenstein GR, Hanauer SB, Sandborn WJ,. The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83.
26. Dignass A, van Assche G, Lindsay JO, et al,.; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
27. Kornbluth A, Sachar DB,; The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
28. Travis SP, Stange EF, Lémann M, et al,.; European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62.
29. Khan KJ, Ullman TA, Ford AC, et al,. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-73.
30. Wang SL, Wang ZR, Yang CQ,. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med 2012; 4: 1051-6.
31. Ohkusa T, Kato K, Terao S, et al,. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010; 105: 1820-9.
32. Kato K, Ohkusa T, Terao S, et al,. Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther 2014; 39: 949-56.
33. Turner D, Levine A, Kolho KL, Shaoul R, Ledder O,. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis 2014; 8: 1464-70.
34. Dewint P, Hansen BE, Verhey E, et al,. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014; 63: 292-9.
35. Scarpignato C, Pelosini I,. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 (Suppl. 1): 36-66.
36. Scarpignato C, Pelosini I,. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73 (Suppl. 1): 13-27.
37. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P,; Retic Study Group (Rifaximin-EIR Treatment in Crohn's Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-81.
38. Jigaranu AO, Nedelciuc O, Blaj A, et al,. Is rifaximin effective in maintaining remission in Crohn's disease? Dig Dis 2014; 32: 378-83.
39. Gionchetti P, Rizzello F, Ferrieri A, et al,. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220-1.
40. Guslandi M, Petrone MC, Testoni PA,. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006; 12: 335.
41. Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F,. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin 2000; 16: 14-20.
42. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D,. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002; 14: 290-5.
43. Maccaferri S, Vitali B, Klinder A, et al,. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010; 65: 2556-65.
44. Eckburg PB, Bik EM, Bernstein CN, et al,. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-8.
45. Kothary V, Scherl EJ, Bosworth B, et al,. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of phe-arg-b-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother 2013; 57: 811-7.
46. Brown EL, Xue Q, Jiang ZD, Xu Y, DuPont HL,. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 2010; 54: 388-96.
47. Schrodt C, McHugh EE, Gawinowicz MA, DuPont HL, Brown EL,. Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. PLoS ONE 2013; 8: e68550.
48. Ma X, Shah YM, Guo GL, et al,. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007; 322: 391-8.
49. Zhang B, Xie W, Krasowski MD,. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008; 9: 1695-709.
50. Cheng J, Shah YM, Gonzalez FJ,. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 2012; 33: 323-30.
51. Koutsounas I, Theocharis S, Patsouris E, Giaginis C,. Pregnane X receptor (PXR) at the crossroads of human metabolism and disease. Curr Drug Metab 2013; 14: 341-50.
52. Zhou C, Tabb MM, Nelson EL, et al,. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 2006; 116: 2280-9.
53. Xie W, Tian Y,. Xenobiotic receptor meets NF-kappaB, a collision in the small bowel. Cell Metab 2006; 4: 177-8.
54. Cheng J, Shah YM, Ma X, et al,. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010; 335: 32-41.
55. Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ,. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1114-22.
56. Langmann T, Moehle C, Mauerer R, et al,. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 26-40.
57. Wilk JN, Bilsborough J, Viney JL,. The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease. Immunol Res 2005; 31: 151-9.
58. Schwab M, Schaeffeler E, Marx C, et al,. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 26-33.
59. Iwamoto J, Saito Y, Honda A, Miyazaki T, Ikegami T, Matsuzaki Y,. Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease. Inflamm Bowel Dis 2013; 19: 1278-84.
60. Mencarelli A, Renga B, Palladino G, et al,. Inhibition of NF-kB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol 2011; 668: 317-24.
61. Terc J, Hansen A, Alston L, Hirota SA,. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Eur J Pharm Sci 2014; 55: 12-9.
62. Mencarelli A, Migliorati M, Barbanti M, et al,. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 2010; 80: 1700-7.
63. Balzan S, de Almeida Quadros C, de Cleva R, Zilberstein B, Cecconello I,. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol 2007; 22: 464-71.
64. Calanni F, Renzulli C, Barbanti M, Viscomi GC,. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo) 2014; 67: 667-70.
65. Takesue Y, Ohge H, Uemura K, et al,. Bacterial translocation in patients with Crohn's disease undergoing surgery. Dis Colon Rectum 2002; 45: 1665-71.
66. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A,. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002; 66: 246-56.